Navigation Links
Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
Date:4/26/2010

DEERFIELD, Ill., April 26 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT™ (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. Takeda recently announced that the product trade name for dexlansoprazole in the U.S. would be changed from KAPIDEX™ to DEXILANT. The formulation, indication and approved dosages of DEXILANT remain the same as that of KAPIDEX, which was originally approved by the U.S. Food and Drug Administration (FDA) in January 2009. After receiving reports of dispensing errors with KAPIDEX, Takeda, in coordination with the FDA, determined that in the interest of patient safety a name change would be the best way to minimize future errors.  

DEXILANT is a once-daily, oral medication indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication.

"Takeda's response to this situation further demonstrates our commitment to patient safety. We are working to ensure a seamless transition from KAPIDEX to DEXILANT to mitigate any disruption to patient care," said Tim Rudolphi, vice president of marketing at Takeda. "Over the past several months, we conducted a comprehensive communication plan to educate pharmacists, reaching out to more than 45,000 pharmacies, and other health care professionals, including all major prescription insurers and drug wholesalers, about the name change. Today we will begin expanding these efforts to also reach consumers."
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Leading Varian-Equipped Proton Therapy Center Treats 100th Patient
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
5. New Proton Therapy Equipment Enables More Tumors to be Treated
6. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
7. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
8. Neurocrine Advances VMAT2 Inhibitor Program
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
11. TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... YORK , Oct. 31, 2014 Though ... cell technologies are expected to show an annual increase ... market value of nearly $1 billion, according to Kalorama ... revenues from proprietary stem cell therapeutics that have gained ... authorities. "As drug developers tackle ever more ...
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... Oct. 30, 2014   ViaDerma, Inc. ... bringing new products to market, has recently released ... TetraStem is a topical liquid tetracycline-based antibiotic that ... can convert oral medication active ingredients into topical ... first aid antibiotic to help prevent skin infection ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... (NYSE: BSX ) today announced financial results for the ... for net sales and earnings per share (EPS) for the ... highlights (Sales growth rates are constant currency): , ... EPS of $0.19, both within the Company,s guidance ranges ...
... NEW ORLEANS, Oct. 19 NCPA 111th Annual Convention ... in targeted pharmacy-based patient care services, has announced the ... National Community Pharmacists Association,s annual convention, MirixaEdge enables pharmacists ... of their patients regardless of health plan, employer, or ...
Cached Medicine Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 27Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 28Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 29Mirixa Corporation Announces MirixaEdge(SM) 2
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... Americans say that either they or a family member ... the latest issue of The Gerontological Society of America,s ... ), which goes on to show that Americans strongly ... patients, end-of-life health care wishes. , This PP&AR ... ," features 12 articles that present new ways of ...
(Date:10/31/2014)... 2014 North Shore Eye Care today ... Long Island and the addition of leading ophthalmologist, William ... to North Shore Eye Care Medical Director, Jeffrey Martin, ... of the Department of Ophthalmology of Winthrop-University Hospital and ... City for more than 30 years. He has been ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... of the most remarkable gifts of life — building ... for matching extraordinary surrogate mothers and donors with hopeful ... individuals in unforeseen circumstances. , It’s a collective aptitude ... surrogacy agencies, surrogacy lawyers, and fertility clinics that help ...
(Date:10/31/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... U.S. indoor air quality (IAQ) market is expected to grow ... rate (CAGR) of 7% over the next five years. The ... of 7.4%. , Since 2012, continuing media attention focused ... infectious diseases such as bird flu and the increase in ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... INCREASE 23 PERCENTSAN DIEGO, Feb. 17 Volcano Corporation ... development, manufacturing and sales of products for the diagnosis ... reported that revenues for the full year 2008 increased ... for the fourth quarter of 2008 increased 23 percent ...
... and those also taking steroids are most vulnerable, study ... class of medications used widely to treat rheumatoid arthritis ... shingles, especially among older people and those who are ... appearing in the Feb. 18 issue of the ...
... Foresight Credited with Industry,s Strong Business Performance in Tough ... economy in crisis, it,s clear that strong domestic industries ... Food and Drug Administration (FDA) mandated trans fat appear ... products to reduce or eliminate trans fat content. ...
... and partners,of Greenway Medical Technologies, led by the ... Barnes, recently returned from,Washington, D.C. where they played ... healthcare information technology (HIT) portion of,the $787 billion ... law. , Greenway,s leadership ...
... alleviate the stress of trying to figure out the ,Nanny ... - there are two things parents never imagined ... of America,s most exciting female political figures having issues due ... an issue. That,s why Sittercity.com, America,s largest and most ...
... Feb. 17 National Pharmaceutical Council President Dan ... economic stimulus package, which includes $1.1 billion for ... package into law, President Obama has made a ... for comparative effectiveness research also is a major ...
Cached Medicine News:Health News:Volcano Reports Full Year Revenues Increase 31 Percent 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 3Health News:Volcano Reports Full Year Revenues Increase 31 Percent 4Health News:Volcano Reports Full Year Revenues Increase 31 Percent 5Health News:Volcano Reports Full Year Revenues Increase 31 Percent 6Health News:Volcano Reports Full Year Revenues Increase 31 Percent 7Health News:Volcano Reports Full Year Revenues Increase 31 Percent 8Health News:Volcano Reports Full Year Revenues Increase 31 Percent 9Health News:Volcano Reports Full Year Revenues Increase 31 Percent 10Health News:Volcano Reports Full Year Revenues Increase 31 Percent 11Health News:Volcano Reports Full Year Revenues Increase 31 Percent 12Health News:Volcano Reports Full Year Revenues Increase 31 Percent 13Health News:Volcano Reports Full Year Revenues Increase 31 Percent 14Health News:Rheumatoid Arthritis Drugs Raise Shingles Risk 2Health News:Rheumatoid Arthritis Drugs Raise Shingles Risk 3Health News:Farmers' Trans Fat Solution Efforts Preserve $700 Million Market 2Health News:Farmers' Trans Fat Solution Efforts Preserve $700 Million Market 3Health News:Greenway Medical Technologies Assists Capitol Hill With Shaping of The President's Stimulus Package 2Health News:Greenway Medical Technologies Assists Capitol Hill With Shaping of The President's Stimulus Package 3Health News:Sittercity.com Makes Nanny Taxes Less Taxing 2Health News:Sittercity.com Makes Nanny Taxes Less Taxing 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: